HMG (CAS 61825-94-3) is a high-purity human menopausal gonadotropin API, a natural glycoprotein hormone mixture extracted from the urine of postmenopausal women. It contains both follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which play critical roles in regulating reproductive function.
Produced under strict GMP standards, this API ensures consistent bioactivity, purity, and batch-to-batch stability, making it ideal for pharmaceutical formulation. It is widely applied in the development of drugs for assisted reproductive technology (ART), such as in vitro fertilization (IVF), to stimulate follicular development and ovulation. It is also used in the treatment of hypogonadism in both men and women.
Its ability to mimic natural gonadotropin activity makes it an indispensable raw material for both clinical research and large-scale pharmaceutical production, supporting the development of effective treatments for reproductive disorders and fertility enhancement.
